Alexion Pharmaceuticals, Inc. (ALXN)
Stock Price Chart
Key Info
| Market Cap | 22.19B |
| Revenue (ttm) | 5.54B |
| Net Income (ttm) | 846.10M |
| Shares Out | 219.17M |
| EPS (ttm) | 3.81 |
| PE Ratio | 26.57 |
| Forward PE | 9.60 |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Aug 11, 2020 |
| Last Price | $101.24 |
| Previous Close | $101.88 |
| Change ($) | -0.64 |
| Change (%) | -0.63% |
| Day's Open | 102.86 |
| Day's Range | 101.10 - 102.86 |
| Day's Volume | 1,511,755 |
| 52-Week Range | 72.67 - 125.52 |
More Stats
| Market Cap | 22.19B |
| Enterprise Value | 21.95B |
| Earnings Date (est) | Oct 22, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 219.17M |
| Float | 218.56M |
| EPS (basic) | 3.77 |
| EPS (diluted) | 3.81 |
| FCF / Share | 10.73 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | 3.76% |
| FCF Yield | 10.66% |
| Payout Ratio | n/a |
| Shares Short | 4.76M |
| Short Ratio | 2.33 |
| Short % of Float | 2.10% |
| Beta | 1.39 |
| PE Ratio | 26.57 |
| Forward PE | 9.60 |
| P/FCF Ratio | 9.38 |
| PS Ratio | 4.01 |
| PB Ratio | 2.13 |
| Revenue | 5.54B |
| Operating Income | 452.10M |
| Net Income | 846.10M |
| Free Cash Flow | 2.37B |
| Net Cash | 244.00M |
| Net Cash / Share | 1.11 |
| Gross Margin | 83.02% |
| Operating Margin | 8.17% |
| Profit Margin | 15.30% |
| FCF Margin | 42.73% |
| ROA | 10.27% |
| ROE | 8.19% |
| ROIC | n/a |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4,991 | 4,131 | 3,551 | 3,084 | 2,604 | 2,234 | 1,551 | 1,134 | 783 | 541 |
| Revenue Growth | 20.81% | 16.34% | 15.14% | 18.44% | 16.56% | 44% | 36.79% | 44.76% | 44.82% | - |
| Gross Profit | 4,597 | 3,757 | 3,097 | 2,826 | 2,371 | 2,060 | 1,374 | 1,061 | 690 | 477 |
| Operating Income | 2,132 | 386 | 668 | 703 | 601 | 889 | 532 | 404 | 231 | 151 |
| Net Income | 2,404 | 77.60 | 443 | 399 | 144 | 657 | 253 | 255 | 175 | 97.03 |
| Shares Outstanding | 223 | 223 | 224 | 224 | 213 | 198 | 196 | 190 | 183 | 179 |
| Earnings Per Share | 10.70 | 0.35 | 1.97 | 1.76 | 0.67 | 3.26 | 1.27 | 1.28 | 0.91 | 0.52 |
| EPS Growth | 2957.14% | -82.23% | 11.93% | 162.69% | -79.45% | 156.69% | -0.78% | 40.66% | 75% | - |
| Operating Cash Flow | 2,085 | 426 | 1,116 | 1,086 | 675 | 640 | 497 | 411 | 270 | 161 |
| Capital Expenditures | -155 | -213 | -357 | -333 | -286 | -137 | -29.33 | -21.85 | -21.98 | -12.84 |
| Free Cash Flow | 1,930 | 213 | 758 | 754 | 389 | 503 | 468 | 389 | 248 | 148 |
| Cash & Equivalents | 2,750 | 1,564 | 1,474 | 1,293 | 1,385 | 1,962 | 1,515 | 990 | 541 | 362 |
| Total Debt | 2,666 | 3,207 | 3,231 | 3,289 | 3,571 | 165 | 145 | 149 | - | 5.18 |
| Net Cash / Debt | 83.70 | -1,643 | -1,757 | -1,995 | -2,186 | 1,797 | 1,370 | 841 | 541 | 356 |
| Assets | 17,545 | 13,932 | 13,583 | 13,253 | 13,097 | 4,202 | 3,318 | 2,614 | 1,395 | 1,012 |
| Liabilities | 6,273 | 4,767 | 4,690 | 4,560 | 4,838 | 900 | 936 | 643 | 260 | 152 |
| Book Value | 11,272 | 9,165 | 8,893 | 8,694 | 8,259 | 3,302 | 2,382 | 1,971 | 1,134 | 860 |
Company Profile
Company Details
| Full Name | Alexion Pharmaceuticals, Inc. |
| Country | United States |
| Employees | 3,082 |
| CEO | Ludwig N. Hantson |
Stock Information
| Ticker Symbol | ALXN |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Unique Identifier | NASDAQ: ALXN |
| IPO Date | February 28, 1996 |
Description
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for ALXN 1210 (IV) for the treatment of PNH and aHUS; ALXN1210 (Subcutaneous), which is in Phase I for PNH and aHUS; and Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder. Further, it develops ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830, which is in Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc. to use drug-delivery technology in the development of subcutaneous formulations for its portfolio of products; collaboration with Dicerna Pharmaceuticals, Inc. to discover and develop RNAi therapies for complement-mediated diseases, as well as with Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc. to advance the development of CAEL-101 for light chain amyloidosis; agreement with Stealth BioTherapeutics Corp. to co-develop and commercialize therapy for mitochondrial diseases; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.